BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34681913)

  • 21. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
    Chen J; Fiskus W; Eaton K; Fernandez P; Wang Y; Rao R; Lee P; Joshi R; Yang Y; Kolhe R; Balusu R; Chappa P; Natarajan K; Jillella A; Atadja P; Bhalla KN
    Blood; 2009 Apr; 113(17):4038-48. PubMed ID: 19074726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitors selectively suppress expression of HDAC7.
    Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA
    Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
    Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
    Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
    J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis.
    Abdulrahman N; Leo R; Boumenar HA; Ahmad F; Mateo JM; Jochebeth A; Al-Sowaidi NK; Sher G; Ansari AW; Alam M; Uddin S; Ahmad A; Steinhoff M; Buddenkotte J
    Leuk Lymphoma; 2023 Dec; 64(14):2236-2248. PubMed ID: 37708450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion.
    Zhao L; Hsiao T; Stonesifer C; Daniels J; Garcia-Saleem TJ; Choi J; Geskin L; Rook AH; Wood GS
    J Invest Dermatol; 2022 Dec; 142(12):3253-3261.e4. PubMed ID: 35787399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
    Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
    Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
    Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
    EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
    Fantin VR; Loboda A; Paweletz CP; Hendrickson RC; Pierce JW; Roth JA; Li L; Gooden F; Korenchuk S; Hou XS; Harrington EA; Randolph S; Reilly JF; Ware CM; Kadin ME; Frankel SR; Richon VM
    Cancer Res; 2008 May; 68(10):3785-94. PubMed ID: 18483262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nrf2 Expression and Apoptosis in Quercetin-treated Malignant Mesothelioma Cells.
    Lee YJ; Lee DM; Lee SH
    Mol Cells; 2015 May; 38(5):416-25. PubMed ID: 25896339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment.
    Jakubowicz-Gil J; Langner E; Bądziul D; Wertel I; Rzeski W
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):580-9. PubMed ID: 24126416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor.
    Chakraborty AR; Robey RW; Luchenko VL; Zhan Z; Piekarz RL; Gillet JP; Kossenkov AV; Wilkerson J; Showe LC; Gottesman MM; Collie NL; Bates SE
    Blood; 2013 May; 121(20):4115-25. PubMed ID: 23532732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
    Kavanaugh SM; White LA; Kolesar JM
    Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma.
    Kamstrup MR; Biskup E; Manfè V; Savorani C; Liszewski W; Wirèn J; Specht L; Gniadecki R
    Leuk Lymphoma; 2017 Jan; 58(1):171-178. PubMed ID: 27181628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Response of Mycosis Fungoides Cells to Vorinostat.
    Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
    Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
    Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
    Yuan H; Li AJ; Ma SL; Cui LJ; Wu B; Yin L; Wu MC
    World J Gastroenterol; 2014 May; 20(17):4953-62. PubMed ID: 24833845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.